Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | ERICA: olanzapine to manage T-DXd-related nausea & vomiting in patients with breast cancer

Hitomi Sakai • 15 Sep 2024
ESMO 2024
Breast Cancer Antibodies Trastuzumab deruxtecan
ERICA

Hitomi Sakai, MD, Showa University, Shina-gawa-ku, Tokyo, presented findings from the Phase II ERICA trial (WJOG14320B) of olanzapine for preventing nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) for metastatic breast cancer. The study showed that olanzapine significantly improved complete response (CR) rates in the delayed phase compared to placebo. Olanzapine also reduced nausea rates and days with nausea, and decreased appetite loss. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hitomi Sakai

Managing side effects in prolonged treatment with trastuzumab deruxtecan
0:38
Managing side effects in prolonged treatment with trastuzumab deruxtecan
Hitomi Sakai • 15 Sep 2024
Evaluating the anti-emetic effects of olanzapine for patients treated with T-DXd
0:44
Evaluating the anti-emetic effects of olanzapine for patients treated with T-DXd
Hitomi Sakai • 15 Sep 2024

Related Videos

How can genomic assays guide treatment in HR+/HER2- breast cancer?
1:26
How can genomic assays guide treatment in HR+/HER2- breast cancer?
Kevin Kalinsky • 25 Oct 2026
Disease control and patient-reported quality of life in the ASCENT-04 trial
0:56
Disease control and patient-reported quality of life in the ASCENT-04 trial
Kevin Kalinsky • 25 Oct 2026
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
1:02
postMONARCH : OS of abemaciclib and fulvestrant in HR+/HER2- breast cancer
Kevin Kalinsky • 25 Oct 2026
Treating triple negative early breast cancer after optimal neoadjuvant therapy
2:24
Treating triple negative early breast cancer after optimal neoadjuvant therapy
Joana Ribeiro • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals